打开APP

阿斯利康与MD安德森癌症中心合作开发癌症免疫疗法

  1. MD安德森癌症中心
  2. MedImmune
  3. 免疫疗法
  4. 癌症
  5. 阿斯利康

来源:生物谷 2014-03-19 08:54

阿斯利康旗下MedImmune与MD安德森癌症中心达成合作协议,开发癌症免疫疗法。

2014年3月18日讯 /生物谷BIOON/ --阿斯利康(AstraZeneca)旗下MedImmune单元与MD安德森癌症中心签署了一项为期3年的合作协议,通过MD安德森的登月计划(Moon Shots Program),开发癌症免疫疗法。该协议内容包括转化研究和临床研究。

MD安德森癌症中心于2012年9月宣布启动“登月计划”,旨在提高癌症患者的存活率。新成立的应用癌症科学研究所(IACS)是登月计划的重要平台,该平台将集中资源及丰富的专业知识,以首批8种癌症为攻克对象,包括乳腺癌、卵巢癌、白血病(AMD/MDS)、白血病(CLL)、黑色素瘤、前列腺癌。登月计划的短期目标是显着降低疾病死亡率,长期目标是促进癌症的治愈。

目前,MedImmune正在开展相关临床试验,这些试验中利用了一种新的治疗模式靶向免疫细胞,以改善免疫细胞的抗肿瘤能力,而非靶向肿瘤细胞本身。通过该项合作,MD安德森将在临床上评估MedImmune的免疫治疗分子,以便更好地了解这些分子是如何触发患者的自身免疫反应。

这些研究中收集的数据,将有望揭示免疫系统对肿瘤造成的药物相关变化,最终目的是确定最优组合疗法和开发生物标志物,来指导和评估MedImmune免疫疗法分子的安全性和有效性。

葛兰素史克(GSK)于2012年12月也与MD安德森癌症中心达成了一项合作协议,开发新的治疗性抗体。

免疫疗法(immunotherapy),可帮助机体免疫系统更有效地攻击癌细胞,由于能以多种方式与疾病斗争,已被看做是一个重要的新前沿。目前,已有数家大型制药公司正在开发很有前途的癌症免疫疗法。(生物谷Bioon.com)

英文原文:MedImmune and MD Anderson Agree to Launch Moon Shot at Cancer

The University of Texas MD Anderson Cancer Center and MedImmune agreed to collaborate through MD Anderson’s Moon Shots Program to develop therapies that boost patients’ immune systems to attack their cancers.

“Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective treatments for cancer patients,” said Jim Allison, Ph.D., executive director of the moon shots immunotherapy platform and professor and chair of Immunology at MD Anderson.

The Moon Shots Program was designed to reduce cancer deaths through six “moon shots” targeting eight different types of cancer including breast and ovarian cancers, leukemia (AMD/MDS), leukemia (CLL), melanoma, and prostate cancer. The moon shots are supported by several new research platforms that provide infrastructure, expertise, and technology. The three-year agreement with MedImmune covers translational and clinical research.

MedImmune is conducting clinical trials using a new therapeutic paradigm that targets immune cells to improve their tumor-fighting ability, rather than targeting the tumor cell itself. Through the collaboration, MD Anderson will evaluate several of MedImmune’s immunotherapy molecules in a clinical setting in order to better understand how these molecules elicit immune response in patients.

It is hoped that data collected from these studies will shed light on treatment-related changes to tumors, with the ultimate aim of identifying optimal combination therapies and developing biomarkers to guide and assess the safety and efficacy of MedImmune’s immunotherapy molecules.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->